Cargando…

P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A

Detalles Bibliográficos
Autores principales:	Weisel, Katja, Bahlis, Nizar J, Rodríguez-Otero, Paula, Viqueira, Andrea, Wang, Shen-Wu, Sathiah, Sangeetha, Robinson, Douglas, O’brien, Thomas, Quach, Hang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430942/ http://dx.doi.org/10.1097/01.HS9.0000970536.69350.bb

Ejemplares similares

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A
por: Rodríguez-Otero, Paula, et al.
Publicado: (2023)

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Touzeau, Cyrille, et al.
Publicado: (2023)

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
por: Lesokhin, A. M., et al.
Publicado: (2022)

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
por: Lesokhin, Alexander M., et al.
Publicado: (2023)

S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3
por: Mohty, Mohamad, et al.
Publicado: (2023)

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
por: Manier, Salomon, et al.
Publicado: (2023)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

908. Evaluation of Blood Culture Submission Rates in Japan
por: Tajima, Taichi, et al.
Publicado: (2020)

P9.08 The Quantitative Detection of Mycobacterial Contaminations in Endoscope Reprocessors
por: Hirai, Y., et al.
Publicado: (2006)

MPV908A-ADC driver: The MPV908A ADC VMEbus board driver under LynxOS
por: Abie, Habtamu, et al.
Publicado: (1992)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

P908: FACTORS ASSOCIATED WITH THE CLINICAL PROGNOSTIC PERFORMANCE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY NEXT GENERATION FLOW CYTOMETRY IN MULTIPLE MYELOMA
por: Nandakumar, B., et al.
Publicado: (2022)

Growth of small fatigue cracks in Incoloy-908
por: Mei, Z, et al.
Publicado: (1993)

The mpv908 : more about using and testing it
por: Heinze, W
Publicado: (1993)

MPV908 Analog I/O Driver
por: Abie, H, et al.
Publicado: (1993)

MON-908 Carcinoid Causing Catastrophic Calcemia
por: Franquemont, Stephanie, et al.
Publicado: (2020)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Grosicki, Sebastian, et al.
Publicado: (2023)

Noninvasive alveolar recruitment maneuver induces cytokine release in healthy volunteers
por: Malbouisson, L, et al.
Publicado: (2007)

908. Dismantling Barriers to Hepatitis Elimination: Automated Hepatitis C Screening with Care and Cure by a Primary Care Based Team
por: Xu, Binghong, et al.
Publicado: (2021)

Cytokine release syndrome
por: Shimabukuro-Vornhagen, Alexander, et al.
Publicado: (2018)

Cytokine levels is septic shock
por: Mateu Campos, L, et al.
Publicado: (2015)

Effects of antibiotics on intestinal microcirculation, cytokine release and in-vitro vascular reactivity in septic rats
por: Lehmann, C, et al.
Publicado: (2006)

T-cell receptor activation-associated cytokine release is impaired in septic patients with faecal peritonitis
por: Gore, DG, et al.
Publicado: (2014)

Elimination of cytokine and soluble cytokine receptors by carbon sorbents from blood
por: Anisimova, N, et al.
Publicado: (2010)

P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)
por: Costa, Luciano, et al.
Publicado: (2023)

Rituximab and Cytokine Release Syndrome
por: Kulkarni, Hrishikesh S., et al.
Publicado: (2012)

Serum levels of inflammatory cytokines in leprosy patients
por: de Paula, Lúcia, et al.
Publicado: (2010)

P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Einsele, Hermann, et al.
Publicado: (2023)

Th17 cytokines regulate profibrotic cytokines release by human eosinophils
por: Halwani, Rabih, et al.
Publicado: (2012)

G908R NOD2 variant in a family with sarcoidosis
por: Besnard, Valérie, et al.
Publicado: (2018)

Correction to Lancet Glob Health 2021; 9: e908–09
Publicado: (2021)

Cytokines Are at the Heart of It: Cytokine Release Syndrome Underlies Cardiovascular Effects of CAR T Cell
por: Catino, Anna B.
Publicado: (2020)

P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9
por: Usmani, Saad Z, et al.
Publicado: (2023)

Cytokine Release Syndrome: Current Perspectives
por: Murthy, Hemant, et al.
Publicado: (2019)

Urinary and plasma cytokines in the critically ill
por: Adam, Z, et al.
Publicado: (2006)

Procalcitonin, cytokine and NOx in diabetic ketoacidosis
por: Suwarto, S, et al.
Publicado: (2008)

Cytokines in treated and untreated Pompe patients
por: Karabul, N, et al.
Publicado: (2013)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jaghaqfg051vp4csmkr1gc3eot